All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Orphan Drug Designation to Padeliporfin VTP for Pancreatic Cancer

July 5th 2023

The FDA has granted orphan drug designation to padeliporfin vascular targeted photodynamic therapy for use as a potential therapeutic option in patients with locally advanced pancreatic cancer.

Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC

July 5th 2023

The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.

TAS-102/Bevacizumab Prolongs OS, PFS in Patients With mCRC and Maintained ECOG PS of 0 or 1

July 5th 2023

Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.

Abivertinib Produces Responses in Relapsed/Refractory Marginal Zone Lymphoma

July 5th 2023

Treatment with the irreversible BTK inhibitor abivertinib led to responses and disease control in patients with relapsed/refractory marginal zone lymphoma.

Cancer Experts at Jersey Shore University Medical Center Implanting First Targeted Liver Tumor Treatment Pumps in Patients

July 5th 2023

Jersey Shore University Medical Center is among the first hospitals in New Jersey to provide the HAI pump, which is offered at few hospitals in the country, enabling the N.J. community to stay close to home for care.

FDA Approves Ready-to-Dilute Cyclophosphamide Injection for Various Cancers

July 5th 2023

The FDA has approved a new drug application for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy in the treatment of patients with various types of cancers, including malignant lymphoma, multiple myeloma, and various types of leukemia.

Datopotamab Deruxtecan Significantly Improves PFS in Advanced NSCLC

July 5th 2023

Datopotamab deruxtecan provided a statistically significant improvement in progression-free survival compared with standard-of-care docetaxel in patients with locally advanced or metastatic non–small cell lung cancer who received at least 1 prior line of therapy.

Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases

July 5th 2023

Adagrasib has demonstrated intracranial activity among patients with KRAS G12C–mutated non–small cell lung cancer with untreated central nervous system metastases.

Pepinemab/Trastuzumab With Dendritic Cell Vaccine and Adoptive T-Cell Therapy Under Evaluation in HER2+ Breast Cancer

July 5th 2023

A treatment regimen consisting of pepinemab plus trastuzumab and a dendritic cell vaccine, followed by autologous CD4-positive T cells, is under investigation in a phase 1 trial in patients with metastatic HER2-positive breast cancer.

Disitamab Vedotin Plus Toripalimab Elicits Responses, Safety in Metastatic Urothelial Carcinoma

July 4th 2023

The combination of disitamab vedotin with toripalimab generated responses and displayed a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma, irrespective of HER2 expression.

Pelareorep Plus Paclitaxel Induces Responses in Metastatic HR+/HER2– Breast Cancer

July 3rd 2023

The combination of the oncolytic reovirus pelareorep and paclitaxel generated responses in patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Post-Hoc Analysis Confirms Safety of Maintenance Avelumab in Urothelial Carcinoma

July 3rd 2023

The addition of first-line maintenance avelumab to best supportive care has sustained tolerability in patients with advanced urothelial carcinoma.

huCART19-IL8 Proves Safe and Elicits Durable Responses in CAR T–Pretreated R/R Lymphoma

July 3rd 2023

huCART19-IL8 had acceptable safety and induced durable responses in patients with lymphoma who were refractory or relapsed following second-generation CD19-targeted CAR T-cell therapies, according to data from a first-in-human phase 1 trial.

ONC-392/BNT316 Elicits Clinical Activity in Checkpoint Inhibitor–Resistant NSCLC

July 2nd 2023

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer

July 1st 2023

Lower rates of diarrhea and overall bowel dysfunction were reported with the use of neoadjuvant fluorouracil and oxaliplatin vs neoadjuvant pelvic chemoradiation with fluorouracil (5FCURT) in patients with locally advanced rectal cancer. However, lower rates of other toxicities were reported in patients treated with 5FCURT.

FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer

June 30th 2023

The FDA has granted breakthrough therapy designation to zenocutuzumab for use as a potential therapeutic option in patients with advanced unresectable or metastatic NRG1 fusion–positive pancreatic cancer after disease progression on previous systemic therapy or who have no satisfactory alternative options available.

Ropeginterferon Alfa-2b Produces Responses, Safety in Prefibrotic Primary Myelofibrosis

June 30th 2023

Harry Gill, MD, discusses the rationale for exploring ropeginterferon alfa-2b as a potential treatment option for patients early myelofibrosis and expands on the efficacy and safety data observed in the phase 2 study.

Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Low-Grade Serous Ovarian Cancer

June 30th 2023

Bradley J. Monk, MD, FACS, FACOG, discusses the rationale for investigating avutometinib plus defactinib in patients with low-grade serous ovarian cancer, key findings from RAMP 201, and how this research may influence the ovarian cancer treatment paradigm going forward.

Genentech Withdraws US Indication for Pralsetinib in Advanced or Metastatic RET+ Medullary Thyroid Cancer

June 30th 2023

The US indication for pralsetinib in the treatment of adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy has been voluntarily withdrawn by Genentech.

Fox Chase Cancer Center Study Challenges Assumptions About Cystic Renal Masses

June 30th 2023

A new study from Fox Chase Cancer Center that was featured on the cover of the Journal of Urology, published by Wolters Kluwer sheds more light on cystic renal masses.